Payment overview · 2025
General Payments
$199.56
5 reported records · 3 companies
Healthcare provider profile · identity verified
Johnnie Moultrie, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOPE MILLS, NC · NPI 1609882117
Verified facts
What the public records show
CMS Open Payments records show Johnnie Moultrie, MD received $199.56 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 60.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.00 | 60.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.93 | 33.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.56 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.93 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 147 |
| Omeprazole | Omeprazole | 359 | 82 |
| Gabapentin | Gabapentin | 337 | 79 |
| Lisinopril | Lisinopril | 297 | 72 |
| Montelukast Sodium | Montelukast Sodium | 292 | 73 |
| Simvastatin | Simvastatin | 240 | 59 |
| Potassium Chloride | Potassium Chloride | 233 | 66 |
| Metformin Hcl | Metformin Hcl | 209 | 57 |
| Meloxicam | Meloxicam | 204 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 27 |
| Furosemide | Furosemide | 158 | 40 |
| Sertraline Hcl | Sertraline Hcl | 158 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 40 |
| Eliquis | Apixaban | 134 | 28 |
| Losartan Potassium | Losartan Potassium | 130 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 42 |
| Ozempic | Semaglutide | 125 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 46 |
| Jardiance | Empagliflozin | 109 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 29 |
| Chlorthalidone | Chlorthalidone | 99 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 34 |
| Spironolactone | Spironolactone | 96 | 27 |
| Carvedilol | Carvedilol | 93 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 19 |
| Tramadol Hcl | Tramadol Hcl | 73 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 15 |
| Allopurinol | Allopurinol | 58 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 18 |
| Bupropion Xl | Bupropion Hcl | 51 | 11 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Famotidine | Famotidine | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 11 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 13 |
| Valacyclovir | Valacyclovir Hcl | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Linzess | Linaclotide | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Naproxen | Naproxen | 39 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 17 |
| Glipizide | Glipizide | 36 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Prednisone | Prednisone | 35 | 27 |
| Meclizine Hcl | Meclizine Hcl | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 12 |
| Baclofen | Baclofen | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 19 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Finasteride | Finasteride | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.56 · 5 records | Lilly USA, LLC | OTEZLA, REPATHA, TRELEGY ELLIPTA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error